Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...

The firm is testing the modified nucleotide drug ateganosine in a Phase II study with a PD-1 inhibitor in patients with non-small cell lung cancer.

In the meeting, the firm will discuss with the agency new, positive three-month data from the pediatric cohort of the Phase I/II OPGx-LCA5-1001 trial.

By leveraging EEG biomarkers, Alto Neuroscience seeks to target patient subgroups in psychiatry by matching therapies to biology.

The development partners said they will share data with regulators, and AstraZeneca said it will harmonize its share listing across international stock exchanges.

The firms reported promising data from two trials of zipalertinib in patients who have received prior EGFR exon 20-directed therapy and those who haven't.

The funding will support the firm's pipeline of mRNA and gene correction therapies, including an investigational inhaled mRNA therapy under testing for cystic fibrosis.

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...

Retrospective research from more than a decade ago demonstrated the potential benefit, but it hadn't been confirmed in a ...

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.

Researchers still see potential for the TIL therapy to benefit patients if combined with other immunotherapies, like checkpoint inhibitors.